Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ambiante Health & Wellness vs PauseRX

Ambiante Health & Wellness
Graded #449

Lower grade

vs+13.5
PauseRX
Graded #149

Higher grade

The verdict

PauseRX takes it — 68.5/100 to 55/100.

PauseRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. PauseRX is a nationwide compounded GLP-1 telehealth platform notable for its transparency: it names its 503A pharmacy partner (Strive Pharmacy in Gilbert, AZ), its physician network (Beluga Health), and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valuePauseRX +21
45
66
Dose & formulationPauseRX +45
40
85
Clinical oversightPauseRX +5
78
83
Labs & monitoringAmbiante Health & Wellness +1
53
52
FulfillmentAmbiante Health & Wellness +4
65
61
Contract termsAmbiante Health & Wellness +14
55
41
Ambiante Health & Wellness · left barPauseRX · right bar

The numbers

MetricAmbiante Health & WellnessPauseRX
WeighScore55/10068.5/100
GradeCC
Scorecard rank#449#149
SemaglutideNot disclosed$199/mo
TirzepatideNot disclosed$249/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only

Strengths

  • Compounded semaglutide and tirzepatide plus a low-dose GLP-1 "Longevity Microdose" option, all provider-guided
  • Concierge model: dedicated provider, direct secure messaging, provider-directed dosing, and structured check-ins
  • Every plan bundles compounded medication, provider care, and discreet direct delivery with no hidden fees
  • No charge if you are not approved; published support hours (Mon-Fri, 9am-5pm ET) by phone and email

Where it loses points

  • GLP-1 program pricing is not published on the site — quoted only after provider review, so cost is not comparable up front
  • Compounding pharmacy partners are not publicly named (a transparency gap for medication sourcing)
  • No brand-name Wegovy, Zepbound, Mounjaro, or Ozempic — compounded formulations only
  • State availability is not published; private-pay only, and the practice serves women, so it is not a fit for everyone
  • No LegitScript or PCAB accreditation displayed on the marketing site
PauseRX

Graded #149 · C

Strengths

  • Names its 503A pharmacy partner (Strive Pharmacy, Gilbert AZ) — buyers can independently verify its licensure
  • Names its physician network (Beluga Health) — you can research the clinical platform handling your prescriptions
  • Publishes the FDA compounded-medication disclaimer
  • Corporate legal entity disclosed (PauseRX, Inc.) — uncommon for direct-to-consumer GLP-1 platforms
  • Flat $199 'all doses' compounded semaglutide pricing — no per-tier escalation

Where it loses points

  • States served not listed — site claims nationwide, but you must contact support to confirm availability
  • Restrictive cancellation policy — orders can't be changed or canceled once submitted, and medications can't be returned
  • No named medical director (Beluga Health is the network, not a named MD)
  • LegitScript certification number not shown — badge only, so no direct lookup
  • Insurance not accepted — cash-pay only; HSA/FSA eligibility not confirmed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard